Dystrophin is the central protein of the dystrophin-glycoprotein complex (DGC) in skeletal
and heart muscle cells. Dystrophin connects the actin cytoskeleton to the extracellular matrix …

Metformin is a widely accepted first-line hypoglycemic agent in current clinical practice, and
it has been applied to the clinic for more than 60 years. Recently, researchers have …

Leucine zipper-like transcriptional regulator 1 (LZTR1), a substrate adaptor of Cullin 3
(CUL3)-based E3 ubiquitin ligase, regulates proteostasis of the RAS subfamily. Mutations in …

Impaired muscle recovery (size and strength) following a disuse period commonly occurs in
older adults. Many of these individuals are not able to adequately exercise due to pain and …

Dysferlinopathy includes a spectrum of muscle disease characterized by two major
phenotypes: Miyoshi muscular dystrophy (MMD) and limb-girdle muscular dystrophy type 2B …

The 5′ adenosine monophosphate-activated protein kinase (AMPK) is an important
skeletal muscle regulator implicated as a possible therapeutic target to ameliorate the local …

Background: Following injury, older adults exhibit slow recovery of muscle function. Age-
related impairment of sarcolemmal membrane repair may contribute to myocyte death …

Dysferlinopathies refer to a spectrum of muscular dystrophies that cause progressive muscle
weakness and degeneration. They are caused by mutations in the DYSF gene, which …

Pulsed field ablation (PFA) is a promising new treatment for atrial fibrillation (AF), in which
pulmonary vein isolation is achieved by irreversible electroporation. Electroporation causes …

The development of antisense oligonucleotide (ASO)-based therapeutics has made
tremendous progress over the past few years, in particular for the treatment of …